Noxopharm Ltd (ASX:NOX, OTC:NOXOF) has joined a select group of industry pioneers with its newly minted membership of the Alliance for mRNA Medicines (AMM).
AMM is the leading global organisation dedicated to advancing and advocating for mRNA and next generation encoding RNA therapeutics and vaccines.
Promoting mRNA technologies globally
Noxopharm CEO Dr Gisela Mautner said: “AMM is driving the promotion of mRNA-related technologies both in the US and around the world, and advancing policies and regulatory solutions that will allow our industry to grow rapidly and fulfil its promise.
“We are very pleased to join this illustrious group and look forward to playing our part to help shape our collective future.”
AMM’s stated mission is to propel the future of mRNA medicine, improve patients’ lives and advance scientific knowledge by convening and empowering mRNA industry leaders, innovators, scientists and other key stakeholders.
Noxopharm joins the ranks of a group of industry leaders that are pioneering mRNA and other RNA technologies on the global stage, strengthening its position as one of the few Australian companies driving innovation in this area.
Membership also represents a key part of Noxopharm’s strategy to further build and promote its Sofra technology platform, which contains cutting-edge assets such as its SOF[1]VAC™ mRNA vaccine enhancer and SOF-SKN™ lupus medication.
Exponential growth post-COVID
Interest in mRNA technology has grown exponentially following its central role in the success of major COVID-19 vaccines and has the potential to create much-needed new drugs and other vaccines for numerous diseases.
Data from Precedence Research indicates that the mRNA market in 2022 was US$40 billion and is expected to reach US$137 billion by 2032 at a compound annual growth rate of 13%.
Noxopharm plans to participate in various AMM initiatives across its operations, including in crucial areas such as the development of new regulatory frameworks, as well as knowledge sharing and R&D.
A deeper understanding of the evolving regulatory landscape will help the company operationally as it moves to bring its Sofra assets to the clinic and patients.
Groundbreaking work
AMM executive director Clay Alspach said: “We are delighted to welcome Noxopharm into the Alliance and believe that the team can make a real contribution to our organisation, especially in the Asia Pacific region.
“Noxopharm’s groundbreaking work offers an attractive addition to the wide range of new and emerging technologies represented by our members.”